CTRT
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The patient signed the informed consent form and voluntarily joined the study; 2. Age 18-75, male or female; 3. Patients with malignant gastrointestinal tumors confirmed by histopathology or cytology; 4. The subject is currently receiving a 21 day cancer treatment program (excluding other tumor treatment cycles), and needs to use one or more of the following chemotherapy drugs: 1) Gemcitabine 2) Platinum 3) Taxol 4) Fluorouracil: Fluorouracil, Capecitabine, Tegio 5. It can accept the current tumor treatment scheme for at least 3 cycles; 6. The investigator determined that the patient could receive the drug of Herteppa; 7. The subject had grade 2 or more thrombocytopenia in the last anti-tumor treatment cycle, which is defined as platelet count (PLT) = 75 × 109/L And the platelet value in this cycle recovers to = 100 × 109/L, resume anti-tumor treatment; 8. Life expectancy at screening = 12 weeks; 9. ECOG: 0-2 points; 10. The main organs function normally without serious complications.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breast-feeding women; 2. Inability to understand the nature of the research or to obtain informed consent; 3. Other conditions that the investigator determines are not suitable for inclusion in the study; 4. Thrombocytopenia caused by other causes other than thrombocytopenia caused by tumor treatment (such as chronic liver disease, sepsis, disseminated intravascular coagulation, immune thrombocytopenia, etc.); 5. Participants with blood history or tumor bone marrow infiltration; 6. Participants receiving synchronous radiotherapy; 7. Arterial or venous thrombosis events in the last 6 months; 8. There are infections that are difficult to control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The response rate of Herombopag; | — |
Secondary
| Measure | Time frame |
|---|---|
| The lowest platelet value from the beginning of treatment to the end of treatment period;;The time of platelet < 50×109/L from the beginning of treatment to the end of treatment period;;At least one times platelet infusion rate or the proportion of rescue therapy prescribed by the protocol;;The changes of platelet values during the follow-up period;;Security; | — |
Countries
China
Contacts
Public ContactHewei
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed